Organon's Vtama Cream for Atopic Dermatitis Showed Improvement in Disease Severity in Clinical Study

MT Newswires Live07-24

Organon (OGN) said Friday that a post hoc analysis of pooled data from two phase 3 trials show that Vtama cream for the treatment of atopic dermatitis and plaque psoriasis demonstrated early and consistent improvements in disease severity.

Across the three pediatric age groups, therapeutic responses in patients with moderate to severe atopic dermatitis emerged as early as week 2 and continued through the end of the 8-week treatment period, according to the company.

Children comprised roughly 80% of the pooled trial population. Mild-to-moderate cases of folliculitis, headache, and nasopharyngitis were the most common treatment-emergent adverse events in the atopic dermatitis group, the company said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment